RSLS Quote, Financials, Valuation and Earnings

Electromed has a net margin of -68.98% compared to Reshape Lifesciences's net margin of 12.06%. Reshape Lifesciences's return on equity of -172.58% beat Electromed's return on equity of 16.57%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 54004.41%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 83.66%. Given that Reshape Lifesciences has higher upside potential than Electromed, analysts believe Reshape Lifesciences is more attractive than Electromed.

Reshape Lifesciences has a beta of 1.166, which suggesting that the stock is 16.59% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $1.1M, which are smaller than Electromed quarterly revenues of $15.7M. Reshape Lifesciences's net income of $1.5M is lower than Electromed's net income of $1.9M. Notably, Reshape Lifesciences's price-to-earnings ratio is 0.01x while Electromed's PE ratio is 23.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.01x versus 2.66x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -14.17%. Reshape Lifesciences's return on equity of -172.58% beat IRIDEX's return on equity of -218.69%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 54004.41%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 100%. Given that Reshape Lifesciences has higher upside potential than IRIDEX, analysts believe Reshape Lifesciences is more attractive than IRIDEX.

Reshape Lifesciences has a beta of 1.166, which suggesting that the stock is 16.59% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.566, suggesting its less volatile than the S&P 500 by 43.407%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $1.1M, which are smaller than IRIDEX quarterly revenues of $11.9M. Reshape Lifesciences's net income of $1.5M is higher than IRIDEX's net income of -$1.7M. Notably, Reshape Lifesciences's price-to-earnings ratio is 0.01x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.01x versus 0.34x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -35.24%. Reshape Lifesciences's return on equity of -172.58% beat Myomo's return on equity of -38.11%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 54004.41%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 335%. Given that Reshape Lifesciences has higher upside potential than Myomo, analysts believe Reshape Lifesciences is more attractive than Myomo.

Reshape Lifesciences has a beta of 1.166, which suggesting that the stock is 16.59% more volatile than S&P 500. In comparison Myomo has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.863%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $1.1M, which are smaller than Myomo quarterly revenues of $9.8M. Reshape Lifesciences's net income of $1.5M is higher than Myomo's net income of -$3.5M. Notably, Reshape Lifesciences's price-to-earnings ratio is 0.01x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.01x versus 2.02x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -77.93%. Reshape Lifesciences's return on equity of -172.58% beat Stereotaxis's return on equity of -174.6%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 54004.41%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 100%. Given that Reshape Lifesciences has higher upside potential than Stereotaxis, analysts believe Reshape Lifesciences is more attractive than Stereotaxis.

Reshape Lifesciences has a beta of 1.166, which suggesting that the stock is 16.59% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.440, suggesting its more volatile than the S&P 500 by 43.964%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $1.1M, which are smaller than Stereotaxis quarterly revenues of $7.5M. Reshape Lifesciences's net income of $1.5M is higher than Stereotaxis's net income of -$5.8M. Notably, Reshape Lifesciences's price-to-earnings ratio is 0.01x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.01x versus 7.05x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.